Thioguanine Anhydrous
Myeloid Leukemia Associated With Down Syndrome
Explore 9 assets in Myeloid Leukemia Associated With Down Syndrome →Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Children's Oncology Group
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02521493CT.gov Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Myeloid Leukemia Associated With Down Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Thioguanine Anhydrous (this asset) | Children's Oncology Group | P3 | B · 60 |
| Cytarabine | National Cancer Institute (NCI) | P3 | BB |
| Mitoxantrone | Children's Oncology Group | P3 | B |
| Etoposide | Children's Oncology Group | P3 | B |
| Crisantaspase | Children's Oncology Group | P3 | B |
| Asparaginase | Children's Oncology Group | P3 | B |
| Daunomycin | Children's Oncology Group | P3 | B |
| Uproleselan | National Cancer Institute (NCI) | P1 | CC |
| Fludarabine | National Cancer Institute (NCI) | P1 | CC |
Other indications for Thioguanine Anhydrous
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 73 |
| Acute Lymphoblastic Leukemia | — | P4 | BBB · 72 |
| Lymphoblastic Lymphoma | — | P4 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Thioguanine Anhydrous in Myeloid Leukemia Associated With Down Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/thioguanine-anhydrous-myeloid-leukemia-associated-with-down-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →